Facial reconstruction

Search LJMU Research Online

Browse Repository | Browse E-Theses

Optimising the chick chorioallantoic membrane xenograft model of neuroblastoma for drug delivery

Swadi, R, Mather, G, Pizer, BL, Losty, PD, See, V and Moss, D (2018) Optimising the chick chorioallantoic membrane xenograft model of neuroblastoma for drug delivery. BMC Cancer, 18 (1).

s12885-017-3978-x (1).pdf - Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview


Background Neuroblastoma is a paediatric cancer that despite multimodal therapy still has a poor outcome for many patients with high risk tumours. Retinoic acid (RA) promotes differentiation of some neuroblastoma tumours and cell lines, and is successfully used clinically, supporting the view that differentiation therapy is a promising strategy for treatment of neuroblastoma. To improve treatment of a wider range of tumour types, development and testing of novel differentiation agents is essential. New pre-clinical models are therefore required to test therapies in a rapid cost effective way in order to identify the most useful agents. Methods As a proof of principle, differentiation upon ATRA treatment of two MYCN-amplified neuroblastoma cell lines, IMR32 and BE2C, was measured both in cell cultures and in tumours formed on the chick chorioallantoic membrane (CAM). Differentiation was assessed by 1) change in cell morphology, 2) reduction in cell proliferation using Ki67 staining and 3) changes in differentiation markers (STMN4 and ROBO2) and stem cell marker (KLF4). Results were compared to MLN8237, a classical Aurora Kinase A inhibitor. For the in vivo experiments, cells were implanted on the CAM at embryonic day 7 (E7), ATRA treatment was between E11 and E13 and tumours were analysed at E14. Results Treatment of IMR32 and BE2C cells in vitro with 10 μM ATRA resulted in a change in cell morphology, a 65% decrease in cell proliferation, upregulation of STMN4 and ROBO2 and downregulation of KLF4. ATRA proved more effective than MLN8237 in these assays. In vivo, 100 μM ATRA repetitive treatment at E11, E12 and E13 promoted a change in expression of differentiation markers and reduced proliferation by 43% (p < 0.05). 40 μM ATRA treatment at E11 and E13 reduced proliferation by 37% (p < 0.05) and also changed cell morphology within the tumour. Conclusion Differentiation of neuroblastoma tumours formed on the chick CAM can be analysed by changes in cell morphology, proliferation and gene expression. The well-described effects of ATRA on neuroblastoma differentiation were recapitulated within 3 days in the chick embryo model, which therefore offers a rapid, cost effective model compliant with the 3Rs to select promising drugs for further preclinical analysis.

Item Type: Article
Uncontrolled Keywords: 1112 Oncology and Carcinogenesis; 1117 Public Health and Health Services; Oncology & Carcinogenesis
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RS Pharmacy and materia medica
Divisions: Pharmacy & Biomolecular Sciences
Publisher: BMC (Part of Springer Nature)
SWORD Depositor: A Symplectic
Date Deposited: 15 Feb 2024 11:43
Last Modified: 15 Feb 2024 11:43
DOI or ID number: 10.1186/s12885-017-3978-x
URI: https://researchonline.ljmu.ac.uk/id/eprint/22629
View Item View Item